A Pharma Manufacturer's View of Quality by Design - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Pharma Manufacturer's View of Quality by Design
Pfizer's Experience with QbD. This article is part of a special issue on Outsourcing.


Pharmaceutical Technology
Volume 35, pp. s34-s39

Benefits of QbD

Strongly focused on collaboration between research and manufacturing, QbD advances process understanding for increased effectiveness and efficiency. The "real time, real data" sharing of industry knowledge optimizes front-end design to more fully support the product life cycle. The science- and risk-based approach boosts regulator confidence by minimizing regulator risk. Because QbD brings medicines to patients in a better-understood and fundamentally more reliable way, consumers benefit as well.

QbD reduces postapproval regulatory submissions, minimizes risk around manufacturing failures and product recalls, trims non-value-added regulatory and compliance activities, and facilitates novel approaches to process validation. At the same time, QbD improves regulatory flexibility, process understanding, and application of technology. QbD hones regulatory-review criteria, capitalizes on experience to leverages industrywide expertise, and fosters global harmonization that will benefit the global pharmaceutical industry, its consumers, and other stakeholders.

QbD concepts coincide with a burgeoning global industry movement toward building quality into pharmaceuticals from development through manufacturing by bridging gaps between pharmaceutical development and manufacturing and using sound science to demonstrate and assure the product's safety, quality, and efficacy throughout its entire life cycle. Launched in 2007, the Product Quality Lifecycle Implementation (PQLI) initiative is a global, industry-led effort led by International Society for Pharmaceutical Engineering to facilitate the implementation of ICH standards.

Pfizer is actively engaged in the PQLI initiatives. In collaboration with the European Federation of Pharmaceutical Industries and Associations, the European Medicines Agency conducted a regulator/industry event around ICH Q8, Q9 and Q10. Pfizer played a key role in facilitating this collaborative initiative. Activities included mock regulatory inspections that were conducted at Pfizer sites and seminars on topics that included product life-cycle management, forward-thinking action steps, and criticality.

Conclusion

The examples cited in this article are just some ways of how QbD is affecting the pharmaceutical industry and its regulatory agencies on a global scale. To facilitate continuous improvement and technical innovation, the global pharmaceutical industry needs a global quality and regulatory framework for postapproval changes. Trying to develop increasingly complicated technologies with fewer resources than were available in the past is an ongoing challenge for the pharmaceutical industry. By enabling pharmaceutical companies to focus on critical and promising products and process areas, QbD and other global harmonization efforts will help the industry meet such challenges. The QbD initiatives in place throughout Pfizer are fostering the vital codevelopment, collaboration, and innovation that position the company to meet 21st century global industry challenges. In harmony with Pfizer's Right First Time and other continuous improvement programs and initiatives, QbD will support Pfizer's global transformation and drive its forward growth.

Vince McCurdy is head of the Right First Time Program Office at Pfizer Global Research & Development, Gerry Migliaccio is senior vice-president of Network Performance for Pfizer Global Supply, Roger Nosal is vice-president of Pfizer Global Chemistry, Manufacturing, and Controls in Pfizer Pharmaceutical Sciences, and James Spavins is vice-president of Global Chemistry, Manufacturing,and Controls & Global Supply Chain in Pfizer Pharmaceutical Sciences.

References

1. FDA, "Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality of Assessment System; Notice of Pilot Program," Fed. Reg. 70 (134), 407619–40720 (July 2005).

2. ICH, Q8 Pharmaceutical Development (2008)

3. ICH, Q9 Quality Risk Management (2005).

4. ICH, Q10 Pharmaceutical Quality Systems (2008).

Note: For related article, see "Global Regulatory Submissions for QbD: Wyeth's Experience in the CMC Pilot," in the October 2009 issue of Pharmaceutical Technology.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here